High XPO6 expression in the PRAD cohort was significantly associated with N classification (OR = 1.71 for N1 vs. N0, P = 3.87E-02), Gleason score (OR = 1.76 for 8–10 vs. 6–7, P = 4.76E-02), targeted molecular therapy (OR = 2.54 for Yes vs. No, P = 2.54E-02), which was consistent with the correlation between XPO6 and clinicopathological characteristics of PCa (Table 2). The gene discussed is XPO6; the disease is posterior cortical atrophy.